ProBiotix Health PLC (AQSE:PBX) has entered into a new commercial partnership in Slovakia, extending the international footprint of its proprietary LPLDL® probiotic ingredient through a collaboration with Slovak probiotics specialist iProbio.
Under the agreement, ProBiotix will supply its patented LPLDL® strain for use in CARDIObiom+®, a newly launched food supplement developed by iProbio, the consumer health brand of PerBiotiX s.r.o. The product is designed to support cardiovascular and metabolic health and marks iProbio’s entry into the growing cardiometabolic wellness market.
New Product Targets Significant Cardiovascular Health Needs
The launch comes against a backdrop of elevated cardiovascular health concerns in Slovakia. According to data from the European Society of Cardiology, cardiovascular disease mortality in the country is estimated to be around 50% above the European Union average, while nearly half of Slovak adults are believed to suffer from hypercholesterolaemia.
CARDIObiom+® was introduced to the market to coincide with World Hypertension Day and a broader international campaign focused on cardiovascular health awareness.
LPLDL® Selected Following Clinical Review
iProbio said it chose ProBiotix’s LPLDL® strain following an extensive assessment of clinically supported ingredients aimed at improving cardiometabolic health.
The new supplement combines LPLDL® with a standardized extract of lemon verbena (Aloysia citrodora) and hibiscus (Hibiscus sabdariffa), alongside vitamins D3 and B1. The formulation is delivered through a dual-capsule daily regimen designed to support cholesterol management, lipid and glucose metabolism, and overall metabolic wellbeing.
Distribution to Begin in Slovakia with Regional Expansion Planned
The product will initially be sold through iProbio’s online sales platform before expanding into pharmacies, health food retailers and distribution partners across Slovakia.
While ProBiotix will provide the LPLDL® active ingredient, iProbio will oversee manufacturing, packaging and commercialization of the product.
The companies also expect to broaden distribution into the Czech Republic and other Central European markets as the partnership develops.
ProBiotix Highlights Growing Commercial Scale
Commenting on the agreement, ProBiotix Chief Executive Steen Andersen said the deal reflects increasing demand for the company’s probiotic technology.
“Our partnership with iProbio to supply our unique LPLDL® strain to be used in their new CARDIObiom+® product is further validation of the growing scalability of our business.
“Increasing awareness of the need to focus on cardiovascular health is critical, and with this partnership agreement we are very pleased that we can help advance further awareness and increase sales in new geographic territories.”
iProbio Sees Opportunity in Cardiometabolic Health Market
iProbio Chief Executive Martin Haranta said the new product represents a strategic expansion of the company’s probiotics portfolio.
“CARDIObiom+® represents a natural next step for iProbio. After more than 40 years of microbiome research, we wanted to expand our targeted probiotic portfolio into the field of cardiometabolic health – a segment where there is strong scientific evidence as well as a clear consumer need.
“LPLDL® is a probiotic strain with clinically validated effects supporting cholesterol metabolism, and our partnership with ProBiotix Health has provided us with confidence both in the scientific foundation and in supply reliability. The product launch on World Hypertension Day also allowed us to naturally connect with the ongoing conversation among Slovak consumers about heart health and metabolic balance. We look forward to further developing this collaboration.”
Leave a Reply